BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 8807097)

  • 1. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
    Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
    Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
    Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor.
    Demirer T; Buckner CD; Storer B; Lilleby K; Rowley S; Clift R; Appelbaum FR; Storb R; Bensinger WI
    J Clin Oncol; 1997 Feb; 15(2):684-90. PubMed ID: 9053494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
    Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
    J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer.
    Demirer T; Rowley S; Buckner CD; Appelbaum FR; Lilleby K; Storb R; Schiffman K; Bensinger WI
    J Clin Oncol; 1995 Jul; 13(7):1714-9. PubMed ID: 7541450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors that influence collection and engraftment of autologous peripheral-blood stem cells.
    Bensinger W; Appelbaum F; Rowley S; Storb R; Sanders J; Lilleby K; Gooley T; Demirer T; Schiffman K; Weaver C
    J Clin Oncol; 1995 Oct; 13(10):2547-55. PubMed ID: 7595706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer.
    Schwartzberg LS; Weaver CH; Birch R; Manner C; Tauer K; Beeker T; Morgan-Ihrig C; MacAneny B; Leff R; Smith R; Hainsworth J; Greco T; Schwerkoske J; Murphy MN; Buckner CD
    J Hematother; 1998 Apr; 7(2):141-50. PubMed ID: 9597571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
    Weaver CH; Schwartzberg LS; Birch R; Greco FA; Hainsworth J; Drapkin R; Campos L; Grapski R; Schwerkoske J; Lautersztain J; Hazelton B; Schnell F; Babcock W; Buckner CD
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study.
    Gazitt Y; Callander N; Freytes CO; Shaughnessy P; Liu Q; Tsai TW; Devore P
    J Hematother Stem Cell Res; 2000 Oct; 9(5):737-48. PubMed ID: 11091498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
    Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
    Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields.
    Weaver CH; Tauer K; Zhen B; Schwartzberg LS; Hazelton B; Weaver Z; Lewkow L; Allen C; Longin K; Buckner CD
    J Hematother; 1998 Jun; 7(3):241-9. PubMed ID: 9621257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.
    Gazitt Y; Akay C; Thomas C
    Stem Cells Dev; 2006 Apr; 15(2):269-77. PubMed ID: 16646673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.